MarketInOut Stock Screener Log In | Sign Up

Context Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Context Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization17.37 mln
Float76.10 mln
Earnings Date11/11/2026

Piotroski F-Score

2 / 9
Weak

1-Year Forecast

4.14
Transformational upside

Relative Strength

6 / 100
Severely lagging

Debt / Equity

0.01
Debt-free

ROE

-74.96
Deeply negative

ROA

-67.61
Deeply negative

Business Description

Context Therapeutics is a Philadelphia-based drug development company focused on finding new ways to treat solid tumor cancers. Its main drug candidate, CTIM-76, is designed to harness the body's own immune cells to seek out and destroy cancer cells that carry a specific protein called Claudin 6. The company works alongside Integral Molecular to advance this approach through a shared licensing and development agreement.

Key Fundamentals

EPS-0.48
ROE-74.96
ROIC-2,899
ROA-67.61
EBITDA, mln-45.84
EV / EBITDA0.42
EV / EBIT0.42

Quote Details

Last 0.1891
Change -0.0126 (-6.25%)
Open 0.203
Volume 1,012,385
Turnover 191,442
Average Volume 1,068,891

Financial Ratios

Leverage Ratio1.21
Current Ratio5.79
Price / Book0.57
Price / Tangible Book0.56
Debt / Equity0.01

Financial Strength

Piotroski F-Score 2 / 9
1-Year Target Price4.14
Short Ratio4.12
Short % of Float5.36

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -20.98% 3 / 100   
1 Month -39.85% 7 / 100   
2 Months -69.61% 4 / 100   
6 Months -91.67% 2 / 100   
1 Year -83.56% 8 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog